Vitamin C May Halt Leukemia Development in Early Blood Disorders

Researchers are exploring whether boosting vitamin C levels could alter the progression of early blood disorders that may lead to leukemia. A recent clinical trial focused on individuals with specific blood conditions that are known precursors to the disease.

The EVITA trial, a randomized, double-blind, placebo-controlled study, tested the effects of 1,000 mg of vitamin C daily on participants with these disorders. Early results indicate that addressing vitamin C deficiency might offer some protective benefits against disease progression.

While the findings are promising, scientists emphasize that the study is in its early stages and more research is needed to confirm long-term outcomes. The trial did not claim to prevent leukemia outright but highlighted a potential role for vitamin C in managing risk factors.

Experts caution that these results should not be interpreted as a definitive treatment, but rather as a step toward understanding how nutritional interventions might influence blood health.

Based on reporting from SciTech Daily (Cancer).

Source: SciTech Daily (Cancer). This article was drafted by AI from that reporting and reviewed by an automated accuracy check before publishing.